Potassium%252525252525252525252525252525252525252525252525252525252525252525252520chloride

# Potassium Chloride ## Overview Potassium chloride (KCl) is an essential electrolyte used to treat or prevent hypokalemia. It is available in oral and intravenous formulations. ## Primary Indications * Treatment of hypokalemia. * Prevention of hypokalemia in patients at risk. ## Adult Dosing * **Oral:** * **Treatment:** Typically 20-100 mEq per day in 2-5 divided doses. Higher doses may be required based on severity of hypokalemia and clinical response. Maximum dose is generally limited by GI tolerance and risk of hyperkalemia. * **Prevention:** Typically 20-40 mEq per day in 1-2 divided doses. * Specific dosing is often guided by serum potassium levels and clinical judgment, and may be adjusted based on local hospital protocols. * **Intravenous (IV):** * **Treatment:** Generally administered at a rate not exceeding 10-20 mEq/hour. Higher infusion rates (up to 40 mEq/hour) may be used in life-threatening hypokalemia with continuous cardiac monitoring, but carry increased risk. Maximum single doses are typically 40 mEq. Total daily dose usually does not exceed 200 mEq. * **Prevention:** Typically 20-40 mEq per day. * IV administration concentration should not exceed 40 mEq/L for peripheral lines and 150 mEq/L for central lines to minimize phlebitis. * **Caution:** Rapid IV administration can be dangerous and may cause cardiac arrest. ## Pediatric Dosing Dosing is highly individualized based on serum potassium, age, weight, and clinical status. Dosing guidelines often range from 1-3 mEq/kg/day orally, divided into doses. IV dosing is typically similar or adjusted based on serum potassium and clinical response, with infusion rates generally kept below 0.5-1 mEq/kg/hour for peripheral lines. Specific protocols should be consulted. ## Dose Adjustments * **Renal Impairment:** Dose reduction is necessary. Monitor potassium closely as renal excretion is impaired. * **Adrenal Insufficiency:** Increased risk of hyperkalemia; monitor potassium closely. ## Contraindications * Hyperkalemia. * Conditions causing excessive potassium retention (e.g., untreated Addison's disease, severe renal impairment, anuria, oliguria). * Digitalis intoxication with associated hyperkalemia. ## Adverse Effects * **Common:** Nausea, vomiting, abdominal pain, diarrhea. * **Serious:** Hyperkalemia (arrhythmias, muscle weakness, paresthesias, paralysis), GI ulceration, bleeding, perforation (especially with sustained-release formulations). ## Key Drug Interactions * **ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs, heparin, trimethoprim:** Increased risk of hyperkalemia. * **Digitalis glycosides:** Hyperkalemia may increase toxicity of digitalis; hypokalemia may enhance digitalis toxicity. * **Neuromuscular blocking agents:** Potassium can affect neuromuscular transmission, potentially altering response. ## Monitoring * Serum potassium levels (frequently, especially with IV administration, high doses, or renal impairment). * Renal function (BUN, creatinine). * ECG (especially with rapid IV infusion or suspected hyperkalemia). * Signs and symptoms of hypokalemia and hyperkalemia. ## Clinical Pearls * Oral potassium supplements can be irritating to the GI tract; taking with food or a full glass of water may help. * Sustained-release oral formulations may reduce GI irritation but can cause localized ulceration or bleeding. * IV potassium must be diluted and administered slowly; never give as a rapid IV push or bolus. * Always confirm the concentration and rate of infusion for IV potassium. *** *Disclaimer: This information is intended for clinical use and does not replace comprehensive drug references. Always verify current prescribing information and consult institutional guidelines.*